In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 160-166

  Cloven, Noelle Gillette ^a   Kyshtoobayeva, Ainura ^b   Burger, Robert A ^a   Yu, Ing Ru ^b   Fruehauf, John P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Oncotech Inc   (United States)

Author keywords

Biomarkers; Chemoresistance; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; PACLITAXEL; PROTEIN P53; TOPOTECAN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; CANCER CLASSIFICATION; CLASSIFICATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG RESISTANCE; DRUG RESPONSE; ENDOMETRIOID CARCINOMA; EPITHELIUM CELL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METABOLISM; MUCINOUS CARCINOMA; MULTIDRUG RESISTANCE; OVARY CANCER; OVARY TUMOR; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNDIFFERENTIATED CARCINOMA;

EID: 0742307268     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.09.030     Document Type: Article

References (40)

1. Swenerton K.D., Hislop T.G., Spineeli J., LeRiche J.C., Yang N., Boyles D.A. Ovarian carcinoma: a multivariate analysis prognostic factors. Obstet. Gynecol. 65:1985;264-269.
2. Omura G.A., Brady M.F., Homesley H.D., Yordan E., Major F.J., Buschsbaum H.J., Park R.C. Long term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the gynecologic oncology group experience. J Clin Oncol. 9:1991;1138-1150.
3. Makar A.P., Baekelandt M., Trope C.G., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol. 56:1995;175-180.
4. Krag K.J., Canellos C.T., Griffiths C.T., Knapp R.C., Parker L.M., Welch W.R.et al. Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol. Oncol. 34:1989;88-93.
5. Heintz A.P., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Creasman W.T.et al. Carcinoma of the Ovary. J. Epidemiol. Biostat. 6(1):2001.
6. Frankendal B., Veress B. Importance of histologic grading in prognosis of epithelial ovarian carcinoma. Obstet. Gynecol. 59:1982;576-582.
7. Serov S.F., Scully R.E., Sobin L.J. Histologic typing of ovarian tumors: International Histological Classification of Tumors. 1973;World Health Organization, Geneva.
8. Czernobilsky B., Silverman B.B., Mikuta J.J. Endometrioid carcinoma of the ovary: a clinicopathologic study of 75 cases. Cancer. 26:1970;1141-1152.
9. Sugiyama T., Kamura T., Kigawa J., Terakawa N., Kikuchi Y., Kita T.et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histology with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 88:2000;2584-2589.
10. Behbakht K., Randall T.C., Benjamin I., Morgan M.A., King S., Rubin S.C. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol. Oncol. 70:1998;255-258.
11. Eisenhauer E.A., Vermorken J.B., van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8:1997;963-968.
12. Naik R., Nordin A., Cross P.A., Hemming D., de Barros Lopes A., Monaghan J.M. Complete cytoreduction: is epithelial ovarian cancer confined to the pelvis biologically different from bulky abdominal disease? Gynecol. Oncol. 1999;176-180.
13. Jacobs A.J., Deligdisch L., Deppe G., Cohen C.J. Histologic correlates of virulence in ovarian adenocarcinoma. Am. J. Obstet. Gynecol. 143:1982;574-580.
14. Mehta R.S., Bornstein R., Ing-Ru Yu., Parker R.J., McLaren C.E., Nguyen K.P.et al. Fruehauf Breast cancer survival and In vitro tumor response in the extreme drug resistance assay. Breast Cancer Res. Treat. 1915:2001;1-12.
15. Holloway R.W., Mehta R.S., Finkler N.J., Li K-T., McLaren C.E., Parker R.J.et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol. Oncol. 87:2002;8-16.
16. Kern D.H., Weisenthal L.M. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J. Natl. Cancer Inst. 82:1990;582-588.
17. Muggia F.M., Braley P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L.et al. Small, Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 18:2000;106-115.
18. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
19. McMeekin S.D., Burger R.A., Manetta A., Di Saia P.J., Berman M.L. Endometrioid adenocarcinoma of the ovary and it's relationship to endometriosis. Gynecol. Oncol. 59:1995;81-86.
20. Shimizu Y., Kamoi S., Amada S., Hasumi K., Akiyama F., Silverberg S.G. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features - problems involved in the architectural grading system. Gynecol. Oncol. 70(1):1998;2-12.
21. Kaern J., Trope C.G., Abeler V.M. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian radium hospital from 1979 to 1982. A review of clinicopathological features and treatment modalities. Cancer. 71:1993;1810.
22. Meden H., Marx D., Rath W., Kron M., Fattahi-Meibodi A., Hinney B.et al. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in cox proportional hazards multiple regression. Int. J. Gynecol. Pathol. 13(1):1994;45-53.
23. Rubin S.C., Finstad C.L., Federici M.G., Scheiner L., Lloyd K.O., Hoskins W.J. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer. 73(5A):1994;1456-1459.
24. Harlozinska A., Bar J.K., Sobanska E., Goluda M. p53, c-erbB-2 and p21ras expression in tumor effusion cells in patients with histopathologically different ovarian neoplasms. Anticancer Res. 17(5A):1997;3545-3552.
25. Klemi P.J., Takahashi S., Joensuu H., Kiilholma P., Narimatsu E., Mori M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int. J. Gynecol. 13(3):1994;228-233.
26. Sheridan E., Silcocks P., Smith J., Hancock B.W., Goyns M.H. p53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. Eur. J. Cancer. 30A(11):1994;1701-1704.
27. Kohler M., Janz I., Wintzer H.O., Wagner E., Bauknecht T. The expression of EGFR receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res. 9(6):1989 (Nov-Dec);1537-1547.
28. Felip E., Del Campo J.M., Rubio D., Vidal M.T., Colomer R., Bermejo B. Overexpression of c-erb-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer. 75(8):1995;2147-2152.
29. Tewari K.S., Kyshtoobayeva A.S., Mehta R.S., Yu I-R., Burger R.A., DiSaia P.J.et al. Biomarker conservation in primary and Metastatic epithelial ovarian cancer. Gynecol. Oncol. 78:2000;130-136.
30. Rubin S.C., Finstad C.L., Wong G.Y., Alamadrones L., Plante M., Lloyd K.O. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am. J. Obstet. Gynecol. 168(1 Pt 1):1993;162-169.
31. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R.et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50(13):1990;4087-4091.
32. Kacinski B.M., Mayer A.G., King B.L., Carter D., Chambers S.K. NEU overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol. Oncol. 44:1992;245-253.
33. Di Leo A., Gancberg D., Larsimont D., Tanner M., Jarvinen T., Rouas G.et al. HER-amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer. Res. 8:2002;1107-1116.
34. Teneriello M.G., Ebina M., Linnoila R.I., Henry M., Nash J.D., Park R.C.et al. p53 and Ki-ras mutations in epithelial ovarian neoplasms. Cancer Res. 53(13):1993;3103-3108.
35. Zheng J., Benedict W.F., Xu H.J., Hu S.X., Kim T.M., Velicescu M.et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J. Natl. Cancer Inst. 87(15):1995;1146- 1153.
36. Zorn K.K., Awtry C.S., Gardner G.J., Barrett C., Boyd J.A., Birrer M.J. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancers. Gynecol. Oncol. 88:2003;88-200. Abstract #90.
37. Kurbacher C.M., Grecu O.M., Stier U., Gilster T.J., Janat M.M., Untch M.et al. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Recent Results Cancer Res. 161:2003;221-230.
38. Loizz V., Chan J.K., Osann K., Cappuccini F., Disaia P.J., Berman M.L. The efficacy of individualized chemotherapy selected by in vitro drug resistance testing for women with recurrence epithelial ovarian cancer. Gynecol. Oncol. 88:2003;246. Abstract #189.
39. Fruehauf J.P. Assay assisted treatment selection for women with breast or ovarian cancer. Endocr. Relat. Cancer. 9:2002;171-182.
40. Orr J.W., Orr P., Kern D.H. Cost effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J. Sci. Am. 5:1999;174-178.